AR026605A1 - Un derivado de 6-mercapto-ciclodextrina, su uso, una composicion farmaceutica que lo comprende, un kit para proporcionar bloqueo neuromuscular y sureversion, y un metodo para la reversion del bloqueo neuromuscular inducido por farmacos - Google Patents

Un derivado de 6-mercapto-ciclodextrina, su uso, una composicion farmaceutica que lo comprende, un kit para proporcionar bloqueo neuromuscular y sureversion, y un metodo para la reversion del bloqueo neuromuscular inducido por farmacos

Info

Publication number
AR026605A1
AR026605A1 ARP000106216A ARP000106216A AR026605A1 AR 026605 A1 AR026605 A1 AR 026605A1 AR P000106216 A ARP000106216 A AR P000106216A AR P000106216 A ARP000106216 A AR P000106216A AR 026605 A1 AR026605 A1 AR 026605A1
Authority
AR
Argentina
Prior art keywords
neuromuscular
mercapto
derivative
sureversion
pharmacos
Prior art date
Application number
ARP000106216A
Other languages
English (en)
Spanish (es)
Original Assignee
Adam Worrall Julia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8241767&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR026605(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Adam Worrall Julia filed Critical Adam Worrall Julia
Publication of AR026605A1 publication Critical patent/AR026605A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
    • C08B37/0012—Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/724—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Polymers & Plastics (AREA)
  • Biochemistry (AREA)
  • Materials Engineering (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
ARP000106216A 1999-11-29 2000-11-27 Un derivado de 6-mercapto-ciclodextrina, su uso, una composicion farmaceutica que lo comprende, un kit para proporcionar bloqueo neuromuscular y sureversion, y un metodo para la reversion del bloqueo neuromuscular inducido por farmacos AR026605A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP99309558 1999-11-29

Publications (1)

Publication Number Publication Date
AR026605A1 true AR026605A1 (es) 2003-02-19

Family

ID=8241767

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP000106216A AR026605A1 (es) 1999-11-29 2000-11-27 Un derivado de 6-mercapto-ciclodextrina, su uso, una composicion farmaceutica que lo comprende, un kit para proporcionar bloqueo neuromuscular y sureversion, y un metodo para la reversion del bloqueo neuromuscular inducido por farmacos

Country Status (33)

Country Link
US (3) USRE44733E1 (OSRAM)
EP (1) EP1259550B1 (OSRAM)
JP (2) JP3880041B2 (OSRAM)
KR (1) KR100716524B1 (OSRAM)
CN (1) CN1188428C (OSRAM)
AR (1) AR026605A1 (OSRAM)
AT (1) ATE288450T1 (OSRAM)
AU (1) AU776536B2 (OSRAM)
BE (1) BE2008C047I2 (OSRAM)
BR (1) BRPI0015947B8 (OSRAM)
CA (1) CA2390463C (OSRAM)
CO (1) CO5251450A1 (OSRAM)
CY (1) CY2008018I1 (OSRAM)
CZ (1) CZ298206B6 (OSRAM)
DE (2) DE122008000068I2 (OSRAM)
DK (1) DK1259550T3 (OSRAM)
ES (1) ES2237496T3 (OSRAM)
FR (1) FR08C0052I2 (OSRAM)
HU (1) HU227451B1 (OSRAM)
IL (1) IL149423A0 (OSRAM)
LU (1) LU91501I2 (OSRAM)
MX (1) MXPA02004940A (OSRAM)
NL (1) NL300356I2 (OSRAM)
NO (2) NO328790B1 (OSRAM)
NZ (1) NZ518752A (OSRAM)
PE (1) PE20010902A1 (OSRAM)
PL (1) PL203012B1 (OSRAM)
PT (1) PT1259550E (OSRAM)
RU (1) RU2260013C2 (OSRAM)
SK (1) SK286282B6 (OSRAM)
TW (1) TWI242015B (OSRAM)
WO (1) WO2001040316A1 (OSRAM)
ZA (1) ZA200203538B (OSRAM)

Families Citing this family (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6744471B1 (en) * 1997-12-05 2004-06-01 Olympus Optical Co., Ltd Electronic camera that synthesizes two images taken under different exposures
TWI242015B (en) 1999-11-29 2005-10-21 Akzo Nobel Nv 6-mercapto-cyclodextrin derivatives: reversal agents for drug-induced neuromuscular block
EP1629845A3 (en) * 2000-11-02 2006-03-22 Akzo Nobel N.V. Use of cortisol-sequestering agents for the treatment of hypercortisolaemia related disorders
KR20060096490A (ko) 2003-10-31 2006-09-11 더 유니버시티 오브 캔사스 술포알킬 에테르-알킬 에테르 시클로덱스트린 유도체
EP1735326A4 (en) 2004-01-29 2011-04-20 Pinnacle Pharmaceuticals BETA-CYCLODEXTRIN DERIVATIVES AND THEIR USE AGAINST LETHAL ANTHRAX TOXIN
KR101725225B1 (ko) 2004-04-23 2017-04-12 사이덱스 파마슈티칼스, 인크. 술포알킬 에테르 시클로덱스트린 함유 ｄｐｉ 제형
US7737132B2 (en) 2005-01-28 2010-06-15 Pinnacle Pharmaceuticals β-cyclodextrin derivatives as antibacterial agents
BRPI0520654B8 (pt) 2005-10-26 2021-05-25 Cydex Pharmaceuticals Inc composições de sulfoalquil éter ciclodextrina e processo para preparação das mesmas
US7629331B2 (en) 2005-10-26 2009-12-08 Cydex Pharmaceuticals, Inc. Sulfoalkyl ether cyclodextrin compositions and methods of preparation thereof
US20090069412A1 (en) * 2007-09-09 2009-03-12 Protia, Llc Deuterium-enriched sugammadex
US7635773B2 (en) 2008-04-28 2009-12-22 Cydex Pharmaceuticals, Inc. Sulfoalkyl ether cyclodextrin compositions
US7938283B2 (en) * 2008-06-20 2011-05-10 Grainpro, Inc. System and method for hermetic storage of agricultural commodities during shipping
US10463677B2 (en) 2008-11-07 2019-11-05 Cydex Pharmaceuticals, Inc. Composition containing sulfoalkyl ether cyclodextrin and latanoprost
CN101591402B (zh) * 2009-05-05 2011-11-30 杭州奥默医药技术有限公司 6-脱氧砜类环糊精衍生物及其制备方法
US8492538B1 (en) 2009-06-04 2013-07-23 Jose R. Matos Cyclodextrin derivative salts
DE102010012281A1 (de) * 2010-03-22 2011-09-22 Fresenius Medical Care Deutschland Gmbh Pharmazeutische Zusammensetzungen enthaltend substituiertes 6-Deoxy-6-sulfanylcyclodextrin
CN101864003B (zh) * 2010-06-11 2012-05-02 漆又毛 一种6-脱氧硫醚氨基酸环糊精衍生物的合成方法
WO2012025937A1 (en) 2010-08-25 2012-03-01 Ramamohan Rao Davuluri Improved process for preparation of sugammadex
CN102060941B (zh) * 2010-11-26 2012-12-26 漆又毛 6-脱氧α-氨基酸衍生物环糊精及制备和应用
EP3702374B1 (en) 2012-02-15 2022-03-23 CyDex Pharmaceuticals, Inc. Manufacturing process for cyclodextrin derivatives
HK1211311A1 (en) 2012-02-28 2016-05-20 锡德克斯药物公司 Alkylated cyclodextrin compositions and processes for preparing and using the same
JP5892847B2 (ja) * 2012-04-27 2016-03-23 Ｄｏｗａホールディングス株式会社 シクロデキストリンとシリカ含有物質との複合材料、及びその製造方法、並びにガス吸着剤
GB201211153D0 (en) * 2012-06-22 2012-08-08 Farmhispania Pharmaceutical compositions
EA032006B1 (ru) 2012-10-22 2019-03-29 Сидекс Фармасьютикалс, Инк. Композиции алкилированного циклодекстрина и способы их получения и применения
US9879096B2 (en) * 2013-02-14 2018-01-30 Neuland Laboratories Limited Process for preparation of sugammadex sodium
JP2017523260A (ja) 2014-05-29 2017-08-17 ユーティーアイ リミテッド パートナーシップ シクロデキストリン系のポリアニオン性デンドリマーおよび非イオン性デンドリマー
KR101692884B1 (ko) 2014-06-26 2017-01-04 마루이시세이야쿠가부시키가이샤 안정성을 개선한 로쿠로늄 제제
EP3183295B1 (en) 2014-08-22 2023-08-02 CyDex Pharmaceuticals, Inc. Fractionated alkylated cyclodextrin compositions and processes for preparing and using the same
CN105348412B (zh) * 2014-08-22 2018-06-05 江苏恩华药业股份有限公司 一种舒更葡糖钠的纯化方法
ES3029362T3 (en) 2015-03-19 2025-06-24 Cydex Pharmaceuticals Inc Compositions containing silymarin and sulfoalkyl ether cyclodextrin and methods of using the same
CN104844732B (zh) * 2015-03-27 2017-05-03 山东滨州智源生物科技有限公司 一种舒更葡糖钠的制备方法
WO2016161501A1 (en) * 2015-04-08 2016-10-13 Ling Chang-Chun Pharmaceutical compositions of polyanionic and non-ionic cyclodextrin-based dendrimers and uses thereof
US10494450B2 (en) * 2015-05-29 2019-12-03 Lakshmi Prasad ALAPARTHI Processes for preparation of Sugammadex and intermediates thereof
CN104922693A (zh) * 2015-06-19 2015-09-23 南开大学 一种阴离子型环糊精与抗癌药物包合物及制备方法
CA3001200A1 (en) * 2015-10-07 2017-04-13 Uti Limited Partnership Multifunctional polyanionic cyclodextrin dendrimers
WO2017089978A1 (en) 2015-11-25 2017-06-01 Fresenius Kabi Antiinfectives S.R.L. Crystalline forms of per-chloro-gamma-cyclodextrines
US10414829B2 (en) 2015-11-25 2019-09-17 Fresenius Kabi Ipsum S.R.L. Process for the preparation of sugammadex and its intermediates
ES2810980T3 (es) * 2016-03-22 2021-03-10 Fresenius Kabi Ipsum S R L Un proceso mejorado para la preparación de sugammadex
DK3448395T3 (da) * 2016-04-29 2020-06-02 Alveron Pharma B V Cyclodextriner som prokoagulanter
ES2915423T3 (es) 2016-06-23 2022-06-22 Synthon Bv Proceso de preparación de sugammadex
US10526422B2 (en) 2016-06-29 2020-01-07 Beijing Creatron Institute Of Pharmaceutical Research Co., Ltd. Process for preparation and purification of Sugammades sodium
US20180016359A1 (en) * 2016-06-29 2018-01-18 Beijing Creatron Institute Of Pharmaceutical Research Co., Ltd. Sugammadex preparation and purification method
CN107778383B (zh) * 2016-08-24 2020-03-10 王炳永 一种舒更葡糖钠的精制方法
US10385142B2 (en) 2017-01-23 2019-08-20 Scinopharm Taiwan, Ltd. Method for preparing sugammadex sodium
CN110831588B (zh) 2017-05-03 2023-06-27 锡德克斯药物公司 包含环糊精和白消安的组合物
CN109021148B (zh) * 2017-06-08 2020-11-10 天津科伦药物研究有限公司 一种制备舒更葡糖钠的方法
US10442871B2 (en) 2017-06-22 2019-10-15 Lawrence Livermore National Security, Llc Modified cyclodextrins for the selective sequestration of fentanyl related compounds and uses thereof
EP3421504B1 (en) 2017-06-30 2019-09-18 Synthon B.V. Process for making sugammadex
TWI703163B (zh) * 2017-08-23 2020-09-01 台耀化學股份有限公司 舒更葡糖鈉之製備方法及其晶型
US10233263B1 (en) * 2017-08-23 2019-03-19 Formosa Laboratories, Inc. Method for preparation of sugammadex sodium
US11104746B2 (en) 2017-11-27 2021-08-31 Medichem, S.A. Process for the synthesis of a cyclodextrin derivative
CN107892727B (zh) * 2017-11-27 2019-12-24 合肥博思科创医药科技有限公司 一种舒更葡糖钠的纯化方法
EP3775026B1 (en) 2018-04-06 2022-03-16 Synthon B.V. Purification of sugammadex
KR102054228B1 (ko) 2018-05-28 2019-12-10 연성정밀화학(주) 슈가마덱스 나트륨염의 제조방법
US11634511B2 (en) 2018-06-07 2023-04-25 Merck Sharp & Dohme Llc Processes for the preparation of sugammadex
CN110615860A (zh) * 2018-06-20 2019-12-27 江苏恒瑞医药股份有限公司 一种舒更葡糖钠的纯化方法
HRP20250729T1 (hr) 2018-08-02 2025-08-15 Tapi Croatia Industries Ltd Kruti oblici sugammadeks natrija
WO2020058987A1 (en) * 2018-09-20 2020-03-26 Natco Pharma Limited An improved process for the preparation of sugammadex sodium and its novel polymorphic form
CN112752770A (zh) * 2018-09-27 2021-05-04 韦尔滕施泰因生物制药公司 舒更葡糖的新型晶体形式
JP6950966B2 (ja) * 2018-11-01 2021-10-13 丸石製薬株式会社 スガマデクス又はその薬理学的に許容される塩含有液剤及びその製造方法
CN109438591B (zh) * 2018-12-29 2021-02-09 博瑞生物医药（苏州）股份有限公司 舒更葡糖钠的制备工艺
CN109824800A (zh) * 2018-12-29 2019-05-31 鼎元(天津)生物医药科技有限公司 一种选择性肌松拮抗药舒更葡萄糖钠的制备方法
US20220169753A1 (en) 2019-03-29 2022-06-02 Hospira, Inc. An improved process for preparation of sugammadex acid and sugammadex sodium
CN111978435B (zh) 2019-05-22 2021-05-25 合肥博思科创医药科技有限公司 一种高纯度舒更葡糖钠的制备方法
US11324692B2 (en) 2019-07-03 2022-05-10 Galenicum Health S.L.U. Method to prepare pharmaceutical compositions of suggamadex
EP4023292A4 (en) * 2019-08-30 2023-09-06 TERUMO Kabushiki Kaisha INJECTION FORMULATION
RU2724900C1 (ru) * 2019-10-24 2020-06-26 Маруиси Фармасьютикал Ко., Лтд. Препарат рокурония с улучшенной стабильностью
CN111019016B (zh) * 2019-12-27 2022-02-18 武汉嘉诺康医药技术有限公司 一种舒更葡糖钠杂质的合成方法
WO2021170304A1 (en) 2020-02-28 2021-09-02 Medichem, S.A. Method for drying sugammadex
CN111714459B (zh) * 2020-06-18 2022-06-14 广州瑞尔医药科技有限公司 一种注射用舒更葡糖钠粉针剂及其制备方法
US11097023B1 (en) 2020-07-02 2021-08-24 Par Pharmaceutical, Inc. Pre-filled syringe containing sugammadex
EP3932391A1 (en) 2020-07-03 2022-01-05 Galenicum Health S.L.U. Method to prepare pharmaceutical compositions
US11446325B2 (en) * 2020-09-30 2022-09-20 Cyclolab Cyclodextrin Research And Development Laboratory Ltd. Cyclodextrin derivatives in the treatment or prevention of lysosomal neurodegenerative diseases
US11945788B2 (en) 2021-06-07 2024-04-02 Nuray Chemicals Private Limited Process for preparing pitolisant hydrochloride and solid-state forms thereof
CN113637097A (zh) * 2021-08-10 2021-11-12 北京恒创星远医药科技有限公司 6-全脱氧-6-全碘代-γ-环糊精晶体及其制备方法和应用
CN115708777A (zh) 2021-08-19 2023-02-24 北京费森尤斯卡比医药有限公司 包含巯基环糊精衍生物或其可药用盐的包装药品和保存方法
CN119679816A (zh) * 2023-09-15 2025-03-25 杭州奥默医药股份有限公司 一种用于逆转苄异喹啉类肌松药的肌松拮抗药物

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3929813A (en) 1973-12-26 1975-12-30 Interx Research Corp Novel pro-drug derivatives of pyridinium aldoxime type cholinesterase reactivators and process for preparing same
JPS52108027A (en) 1976-03-09 1977-09-10 Rikagaku Kenkyusho Anticarcinogen
US4816462A (en) 1982-05-18 1989-03-28 Nowicky Wassili Method for diagnosing and for the therapeutic treatment of tumors and/or infectious diseases of different types with alkaloid-compounds
HU194858B (en) 1982-12-03 1988-03-28 Chinoin Gyogyszer Es Vegyeszet Process for producing dibenzo/b,d/pirane derivatives and pharmaceutical compositions containing them
IT1196033B (it) 1984-02-22 1988-11-10 Chiesi Farma Spa Composto ad attivita' antiinfiammatoria ottenuto per complessazione con beta-ciclodestrina e relative formulazioni farmaceutiche
US4727064A (en) 1984-04-25 1988-02-23 The United States Of America As Represented By The Department Of Health And Human Services Pharmaceutical preparations containing cyclodextrin derivatives
GB8506792D0 (en) 1985-03-15 1985-04-17 Janssen Pharmaceutica Nv Derivatives of y-cyclodextrin
GB8613688D0 (en) 1986-06-05 1986-07-09 Euro Celtique Sa Pharmaceutical composition
JPH0819004B2 (ja) 1986-12-26 1996-02-28 日清製粉株式会社 徐放性医薬製剤
HU201783B (en) 1987-10-13 1990-12-28 Chinoin Gyogyszer Es Vegyeszet Process for producing partially methylized carboxy-acyl-beta-cyclodextrines and salts
US5017566A (en) 1987-12-30 1991-05-21 University Of Florida Redox systems for brain-targeted drug delivery
US5002935A (en) 1987-12-30 1991-03-26 University Of Florida Improvements in redox systems for brain-targeted drug delivery
HUT58770A (en) 1989-04-03 1992-03-30 Janssen Pharmaceutica Nv Process for producing regioselective substituted cyclodextrines
US5173481A (en) 1989-04-03 1992-12-22 The United States Of America As Represented By The Department Of Health And Human Services Preparation of specifically substituted cyclodextrins
SU1703657A1 (ru) * 1990-01-23 1992-01-07 Пятигорский фармацевтический институт Соединение включени диэтиламида никотиновой кислоты и @ -циклодекстрина, про вл ющее пролонгированное аналептическое действие
DK0447171T3 (da) 1990-03-15 1994-12-12 Tanabe Seiyaku Co Polysulfat af cyclodextrinderivat og fremgangsmåde til fremstilling deraf
US5180716A (en) * 1990-08-01 1993-01-19 The Regents Of The University Of California Cyclodextrin complexes for neuraxial administration of drugs
US5180176A (en) * 1991-08-08 1993-01-19 Far Great Plastics Industrial Co., Ltd. Elastic truck for roller skates
JP2556236B2 (ja) 1991-08-29 1996-11-20 田辺製薬株式会社 β−シクロデキストリン誘導体のポリ硫酸エステル及びその製法
US5840881A (en) 1992-11-27 1998-11-24 Takeda Chemical Industries, Ltd. Composition containing a water-insoluble or slightly water-soluble compound with enhanced water-solubility
US5767112A (en) 1994-10-21 1998-06-16 Poli Industria Chimica, S.P.A. Muscle relaxant pharmaceutical compositions
AU708107B2 (en) 1994-11-04 1999-07-29 Commonwealth Scientific And Industrial Research Organisation Method for treating animals
GB2307176A (en) * 1995-11-15 1997-05-21 Todd Selwyn Everest Anti-inflammatory clathrating agents for topical use
US5935941A (en) 1997-10-24 1999-08-10 Pitha; Josef Alkylations of cyclodextrins leading to derivatives which have a ridgidly extended cavity
US5834446A (en) * 1996-06-21 1998-11-10 Queen's University At Kingston Nerve process growth modulators
JP4249282B2 (ja) 1998-02-27 2009-04-02 日本食品化工株式会社 新規シクロデキストリン誘導体及びその製造方法
EP1082292B1 (en) 1998-05-29 2005-09-28 Neurosciences Research Foundation Control of pain with endogenous cannabinoids
IL147887A0 (en) 1999-08-13 2002-08-14 Akzo Nobel Nv Use of chemical chelators as reversal agents for drug-induced neuromuscular block
TWI242015B (en) 1999-11-29 2005-10-21 Akzo Nobel Nv 6-mercapto-cyclodextrin derivatives: reversal agents for drug-induced neuromuscular block
US20020111377A1 (en) 2000-12-22 2002-08-15 Albany College Of Pharmacy Transdermal delivery of cannabinoids
WO2002064635A1 (en) 2001-02-14 2002-08-22 Akzo Nobel N.V. 2-alkylated-cyclodextrin derivatives: reversal agents for drug-induced neuromuscular block
TW200402417A (en) 2002-06-21 2004-02-16 Akzo Nobel Nv 1-[(Indol-3-yl)carbonyl]piperazine derivatives

Also Published As

Publication number Publication date
HUP0203755A3 (en) 2003-10-28
JP4563972B2 (ja) 2010-10-20
MXPA02004940A (es) 2003-05-23
SK7262002A3 (en) 2002-11-06
NL300356I2 (nl) 2009-04-01
SK286282B6 (sk) 2008-06-06
DE60017947T2 (de) 2005-06-23
EP1259550B1 (en) 2005-02-02
ZA200203538B (en) 2003-08-04
PE20010902A1 (es) 2001-09-06
HU227451B1 (en) 2011-06-28
CN1402737A (zh) 2003-03-12
FR08C0052I1 (OSRAM) 2009-02-27
DE122008000068I2 (de) 2011-06-16
JP3880041B2 (ja) 2007-02-14
NL300356I1 (nl) 2008-10-01
ES2237496T3 (es) 2005-08-01
PT1259550E (pt) 2005-05-31
BRPI0015947A (pt) 2002-08-20
NO328790B1 (no) 2010-05-18
PL203012B1 (pl) 2009-08-31
LU91501I2 (fr) 2009-01-26
NO20022522D0 (no) 2002-05-28
FR08C0052I2 (fr) 2009-12-18
RU2260013C2 (ru) 2005-09-10
CZ298206B6 (cs) 2007-07-18
EP1259550A1 (en) 2002-11-27
BRPI0015947B8 (pt) 2021-07-06
DK1259550T3 (da) 2005-04-25
JP2003515623A (ja) 2003-05-07
BRPI0015947B1 (pt) 2012-02-07
CA2390463A1 (en) 2001-06-07
PL356097A1 (en) 2004-06-14
US6670340B1 (en) 2003-12-30
TWI242015B (en) 2005-10-21
KR20020063900A (ko) 2002-08-05
DE122008000068I1 (de) 2009-04-23
ATE288450T1 (de) 2005-02-15
HUP0203755A2 (hu) 2003-04-28
DE60017947D1 (de) 2005-03-10
US6949527B2 (en) 2005-09-27
JP2006348301A (ja) 2006-12-28
LU91501I9 (OSRAM) 2019-01-02
CO5251450A1 (es) 2003-02-28
NO2010019I1 (no) 2010-11-22
AU776536B2 (en) 2004-09-16
CN1188428C (zh) 2005-02-09
NO20022522L (no) 2002-05-28
CZ20021814A3 (cs) 2002-08-14
KR100716524B1 (ko) 2007-05-10
NZ518752A (en) 2003-03-28
BE2008C047I2 (OSRAM) 2019-12-11
CY2008018I2 (el) 2009-11-04
US20040029833A1 (en) 2004-02-12
WO2001040316A1 (en) 2001-06-07
CA2390463C (en) 2009-02-03
AU5438001A (en) 2001-06-12
NO2010019I2 (no) 2012-08-27
USRE44733E1 (en) 2014-01-28
HK1049489A1 (en) 2003-05-16
IL149423A0 (en) 2002-11-10
CY2008018I1 (el) 2009-11-04

Similar Documents

Publication Publication Date Title
AR026605A1 (es) Un derivado de 6-mercapto-ciclodextrina, su uso, una composicion farmaceutica que lo comprende, un kit para proporcionar bloqueo neuromuscular y sureversion, y un metodo para la reversion del bloqueo neuromuscular inducido por farmacos
LU91160I2 (fr) Ezetimible ou ses sels acceptés en combinaison avec Simvastatin (Inegy/Vytorin).
LU92146I2 (fr) Dasatinib et ses sels pharmaceutiquement acceptables
CY1105047T1 (el) Ενωσεις πυριδοπυριμιδινονης, η μεθοδος παρασκευης τους και φαρμακευτικες συνθεσεις που τις περιεχουν
EA200400432A1 (ru) Производные мочевины
FI915282A0 (fi) Mono-n-substituerade 1,4,7,10-tetra -azacyklododekanderivat, foerfarande foer deras framstaellning och dessa innehaollande farmaceutiska aemnen.
AR048652A1 (es) 4-fenilamino-quinazolin-6-il-amidas
ES2079534T3 (es) Derivados de polietilenglicol, sus peptidos modificados, metodos para producirlos y uso de los peptidos modificados.
EA200200938A1 (ru) Фармацевтические композиции, содержащие производные азетидина, новые производные азетидина и их получение
CY1106674T1 (el) Αζαδικυκλικοι ετεροκυκλοι σαν ρυθμιστες υποδοχεα κανναβινοειδους
CY1110694T1 (el) Μεθοδος παρασκευης παραγωγων της εχινοκανδινης
NO990583D0 (no) Cykliske eterforbindelser som natriumkanalmodulatorer
AR025103A1 (es) Quelantes quimicos para la reversion del bloqueo neuromuscular inducido por farmacos
DE60316672D1 (de) Polycyclische verbindungen als potenten alpha2-adrenoceptor antagonisten
DE69202286D1 (de) Verfahren zur Färbung keratinischer Fasern mit Isatin oder Isatinderivaten zusammen mit Aminopyrimidin oder Aminopyridin und Färbemittel.
ES2187025T3 (es) Nuevos agentes quelantes de hierro (iii) activos via oral.
AR030203A1 (es) Derivados de carbamato de 2-(s)-hidroximutilina, composiciones farmaceuticas que los comprenden, procedimiento para prepararlos y 2(s), 11-dihidroxi protegida-mutilina como compuesto intermediario
BR9708639A (pt) Composição estabilizadora
IT1317048B1 (it) Uso dell'acido pamoico o di un suo derivato, o di un suo analogo, perla preparazione di un medicamento per il trattamento di patologie
BR9812892A (pt) 2 4-diamino-1,3,5-triazinas substituìdas e seu emprego como herbicidas
AR017851A1 (es) Composicion farmaceutica que comprende un eter carboxialquilico y una estatina, primera composicion farmaceutica para el uso con una segunda composicionfarmaceutica para lograr un efecto hipolipidemico y controlar el riesgo cardiaco adverso en un mamifero y conjunto para lograr dichos efectos terape
BR0308018A (pt) Composto ou um seu sal farmaceuticamente aceitável ou um seu éster hidrolisável in vivo, pró-droga, método para produzir um efeito antibacteriano em um animal de sangue quente, uso de um composto ou um seu sal farmaceuticamente aceitável ou um seu éster hirolisável in vivo, composição farmacêutica, e, processo para a preparação de um composto ou um seu sal farmaceuticamente aceitável ou um seu éster hidrolisável in vivo
PT1197485E (pt) Derivados de ciclobuteno-diona e a sua utilizacao no tratamento da aterosclerose
DK1257552T3 (da) Xanthinderivater, mellemprodukter og anvendelse til behandling af osteoporose
FI960487A0 (fi) Bentsopyraaneja ja niitä sisältäviä farmaseuttisia koostumuksia

Legal Events

Date Code Title Description
FG Grant, registration